MDSpire - Summary
From the Journals

VIS-101 Shows Activity in nAMD Study

Data from a phase 2a study in China suggest visual acuity gains and potential treatment durability

  • March 23, 2026

  • 2 min

Share

The investigational bispecific inhibitor VIS-101, targeting VEGF-A and angiopoietin-2, has shown promising results in a phase 2a study for patients with neovascular age-related macular degeneration (nAMD). Conducted in China with 38 patients aged 50 to 80, the study demonstrated significant improvements in visual acuity—more than 10 letters on the ETDRS scale—and a reduction in retinal thickness after three loading doses. Notably, around two-thirds of participants required no retreatment at four months, with plans for further studies anticipated in 2026.

Original Source(s)

VIS-101 Shows Activity in nAMD Study

  • March 23, 2026

Related Content

Virtual Reality Tests Vision Therapy

Researchers evaluate immersive training for pediatric exotropia.

FDA Approves TECNIS PureSee IOL for Cataract Surgery

First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL

  • March 23, 2026

  • 2 min
The European Myopia Network

A collaborative platform for myopia experts in Europe